Kintara Therapeutics Inc expected to post a loss of 16  cents a share - Earnings Preview

TuHURA Biosciences

08/02/2022 19:33

* Kintara Therapeutics Inc  KTRA.OQ   KTRA.O  is expected
to show
no change in quarterly revenue when it reports  results on
February 10 (estimated). 
    * ​Refinitiv's mean analyst estimate for Kintara
Therapeutics Inc
is for a loss of 16 cents per share. For the same quarter last
year, the company reported a loss of 22 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Kintara
Therapeutics Inc is $5​, about 91.1% above​ its last closing
price of $0.44. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.15       -0.14      -0.17     Missed  -17.2
 Jun. 30 2021  -0.14       -0.16      -0.13     Beat    18.8
 Mar. 31 2021  -0.20       -0.18      -0.23     Missed  -26​
 Dec. 31 2020  -0.14       -0.14      -0.22     Missed  -54.4
 ​​Sep.        -0.09       -0.09      -0.20     Missed  -122.2
 30 2020                                                
 Jun. 30 2020  -0.09       -0.12      -0.33     Missed  -182.8
                                                        ​
 Mar. 31 2020              -0.12      -0.17     Missed  -36
 Dec. 31 2019  -0.17       -0.17      -0.15     Beat    14.3
 This summary was machine generated February 8 at 19:32 GMT.  All
figures in US dollars  unless otherwise stated